SA114. Lurasidone for the Treatment of Adolescent Patients With Schizophrenia: Effect on PANSS Subscales

ABSTRACT: Abstract Background: Lurasidone is an atypical antipsychotic agent that has demonstrated efficacy in the treatment of adults with schizophrenia in the dose range of 40–160 mg/d. The objective of this randomized, double-blind, placebo-controlled study was to evaluate the acute efficacy and safety of lurasidone in adolescent patients with schizophrenia. Methods: Adolescents (13–17 years old) diagnosed with schizophrenia were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Changes from baseline to Week 6 in PANSS total and subscale (positive, negative, general psychopathology, excitability) scores were evaluated using mixed-model, repeated-measures analysis. Treatment response was defined as ≥20% reduction from baseline in PANSS

SUBMITTER: Correll C 

PROVIDER: S-EPMC5476011 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature